
Jun 2, 2026
Assessing Tempus AI (TEM) Valuation After FDA Clearance And New AI Diagnostics Launches
Tempus AI has recently made significant strides with FDA clearance for its xT CDx platform and the launch of new AI diagnostics, attracting renewed interest from investors.Following these announcements, the company's stock experienced notable fluctuations, including a 4.62% increase in a single day and a 14.34% rise over the past week. Despite these gains, Tempus AI's year-to-date performance shows a decline of 15.33%, with a total shareholder return down 16.81% over the past year, indicating a









